Tagraxofusp for children with CD123-positive leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Skin clinical trials.
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 1 to 21 at the time of study enrollment.
- You have a relapsed or resistant blood cancer (like leukemia or certain lymphomas).
- Your cancer cells must test positive for CD123 on a recent sample (by flow cytometry or tissue staining).
- You must fit the study disease status rules (for example: second-or-later relapse, or resistant after several chemotherapy cycles).
- Your body must be healthy enough for treatment (blood counts and heart, kidney, liver, and lung function checks).
- You must have recovered from side effects of prior treatment and meet timing rules for recent chemo, radiation, or other therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TGRX-814 for people with certain blood cancers like non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndromes. It aims to see if the drug is safe and effective.
This early-phase study tests a lab-made immune therapy (CD123 CAR T cells) for children and young adults up to age 21 whose cancer has come back or didn’t respond to treatment. The goal is to see if these CAR T cells can find and attack cancer cells that carry a marker called CD123.
This Phase 1 trial tests MRX-2843 in teenagers and adults whose leukemia has come back or did not respond to prior treatment. The main goals are to find safe dosing and learn how the body processes the drug.
This trial tests a combination of two drugs, tagraxofusp and azacitidine, given as maintenance therapy after a stem cell transplant. The goal is to prevent the leukemia or MDS from coming back in patients whose cancer cells carry a specific marker called CD123.
This trial tests a drug called tagraxofusp combined with a gentle chemotherapy regimen for people whose acute myeloid leukemia (AML) has come back or not responded to an initial venetoclax-based treatment. The study focuses on patients whose leukemia cells have a protein called CD123 on their surface.
This trial tests a new drug combo (tagraxofusp, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML) who have very small amounts of cancer cells still present after initial treatment. The goal is to see if it can clear these leftover cells and prevent the cancer from coming back.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.